UK life sciences industrial strategy
Failure to strike a Brexit deal allowing alignment with the European Medicines Agency would be ‘catastrophic’ for the UK life sciences sector.
The UK can be a leader in cell and gene therapy, but Brexit is a once-in-a-generation challenge
Plan aims to solve long-standing issue of access to medicines
Make NHS best place to research and launch drugs, says ABPI.
No guarantee of funding for new medicines funding – which is being squeezed again
A look ahead to the UK market in 2017 through the eyes of pharma industry leaders